Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,056,053
  • Shares Outstanding, K 95,442
  • Annual Sales, $ 300 K
  • Annual Income, $ -269,950 K
  • EBIT $ -328 M
  • EBITDA $ -343 M
  • 60-Month Beta 0.87
  • Price/Sales 10,258.44
  • Price/Cash Flow N/A
  • Price/Book 8.44

Options Overview Details

View History
  • Implied Volatility 73.61% (-17.31%)
  • Historical Volatility 49.35%
  • IV Percentile 25%
  • IV Rank 19.12%
  • IV High 208.82% on 09/25/25
  • IV Low 41.65% on 01/23/25
  • Expected Move (DTE 13) 3.80 (11.87%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 35
  • Volume Avg (30-Day) 85
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 1,542
  • Open Int (30-Day) 2,332
  • Expected Range 28.22 to 35.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.90
  • Number of Estimates 8
  • High Estimate -0.60
  • Low Estimate -1.13
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.93 +28.44%
on 11/06/25
33.34 -3.96%
on 12/04/25
+7.60 (+31.12%)
since 11/05/25
3-Month
17.91 +78.78%
on 09/15/25
33.34 -3.96%
on 12/04/25
+13.30 (+71.05%)
since 09/05/25
52-Week
9.90 +223.43%
on 04/09/25
33.34 -3.96%
on 12/04/25
+12.39 (+63.12%)
since 12/05/24

Most Recent Stories

More News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - ...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

- BLA for veligrotug successfully submitted to the U.S. Food and Drug Administration (FDA) in late October following recent consultation with the agency - - Veligrotug’s...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - ...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

- Enrollment complete in VRDN-003’s phase 3 clinical trials in thyroid eye disease (TED), REVEAL-1 and REVEAL-2, with each study exceeding its enrollment target due to strong patient demand; topline...

VRDN : 32.02 (-1.36%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 32.02 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

See More

Key Turning Points

3rd Resistance Point 33.70
2nd Resistance Point 33.33
1st Resistance Point 32.68
Last Price 32.02
1st Support Level 31.66
2nd Support Level 31.29
3rd Support Level 30.64

See More

52-Week High 33.34
Last Price 32.02
Fibonacci 61.8% 24.39
Fibonacci 50% 21.62
Fibonacci 38.2% 18.85
52-Week Low 9.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar